BDR Pharmaceuticals
  • Home
    • About BDR
    • CMD Profile
    • News
    • Blogs
    • Our Strengths
    • Facilities
    • Press Release
    • Company Policies
    • CSR Sustainability
    • Mission & Vision
    • Ethical Marketing Division
    • Milestones
    • Global Presence
    • Board of Directors
    About Us
  • Products
    • Innovation & Technology
    • Regulatory
    • Research & Development
    • IPR
    • Quality Policy
    • Contract Manufacturing
    Expertise
    • Culture
    • Job Openings
    Careers
  • Investors
  • Contact
  1. Home
  2. Press Release

Press Release

Innovative Breakthroughs in Pharmaceuticals: Press Releases and Updates

news ET Healthworld
Exclusive Story Jul 01, 2024

BDR Pharma to commercialise furmecil anti-cancer-drug for advanced gastric cancer

Read More
news MoneyControl
Exclusive Story Jul 01, 2024

CCI nods deal to acquire minority stake in BDR Pharma by Multiples Fund III and others

Read More
news Times Of India
Exclusive Story Jul 01, 2024

CCI nods deal to acquire minority stake in BDR Pharma by Multiples Fund III and others

Read More
news Business Today
Exclusive Story Jul 01, 2024

CCI nods deal to acquire minority stake in BDR Pharma by Multiples Fund III and others

Read More
news Business Standard
Exclusive Story Jul 01, 2024

CCI nods deal to acquire minority stake in BDR Pharma by Multiples Fund III and others

Read More
news Mint
Exclusive Story Jul 01, 2024

CCI nods deal to acquire minority stake in BDR Pharma by Multiples Fund III and others

Read More
  • ‹
  • 1
  • 2
  • 3
  • 4
  • ›

Print Media Coverage

The Economic Times

Generic Drug Cos in No hurry to Launch New Covid Products (Editions) - Mumbai, Delhi, Ahmedabad and Hyderabad

Times Of India

60L remdesivir vials to be destroyed as expiry nears (Editions) - Mumbai, Delhi, Ahmedabad and Kolkata

Gujarat Today

BDR Group of Companies continuously growing in the pharmaceutical industry

Mint

Multiples PE picks up 9.3% in BDR Pharma (Editions) - Mumbai, Hyderabad, Chennai, Bangalore, Kolkata, Ahmedabad and Delhi

Financial Express

Multiples PE picks up 9.3% in BDR Pharma (Editions) - Mumbai, Hyderabad, Chennai, Bangalore, Kolkata, Ahmedabad and Delhi

Business Standard (Hindi)

BDR Pharma Raises ₹685 crore from Multiples, Other Investors (Editions) - Mumbai and Delhi

Business Standard

BDR Pharma Raises ₹685 crore from Multiples, Other Investors (Editions) - Mumbai, Hyderabad, Chennai, Bangalore, and Delhi

Business Standard

Multiples PE picks up 9.3% in BDR Pharma (Editions) - Mumbai, Hyderabad, Chennai, Bangalore, Kolkata, Ahmedabad and Delhi

The Economic Times

BDR Pharma Raises ₹685 crore from Multiples, Other Investors (Editions) - Mumbai, Delhi, Chennai, Kolkata and Ahmedabad

The Economic Times

Feeling Better (Editions) - Mumbai, Delhi, Chennai, Kolkata and Ahmedabad

Business Standard

Pharma SMEs stock up a month’s raw material

ET Healthword

BDR Looking to Buy Majority Stake on Drug ib Belarus. (Editions) - Mumbai, Delhi, Bangalore, Ahmedabad, Kolkata, Hyderabad and Chennai

The Economic Times

BDR Pharmaceutical launches generic drug for treating prostate cancer in India

ET Healthworld

BDR launches generic Apalutamide to treat prostate cancer

FE Healthcare

BDR Pharmaceutical launches first generic to treat Prostate cancer in India

  • ‹
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • ›
Discover Previous
News Section
awards-cta
Discover Next
Ethical Marketing
certification-cta
footer-logo

BDR is a “niche” player in both global and domestic arena

Company
About BDR Milestones Our Mission & Vision Our Achivements CMD Profile
Expertise
Innovation & Technology Regulatory Research & Development IPR Quality Policy Contract Manufacturing
Quick Links
Home Products News Careers Contact
Registered Office

BDR Pharmaceuticals Internationals Pvt. Ltd. Registered Office, 407/408, Sharda Chambers, New Marine Lines, Mumbai 400020, India.

+91-22-40560560
Corporate Office

Grievance officer: Mr. Pawan Srivastava

Ombudsman, 6, Engineering Centre, 9 Mathew Road, Opera House, Mumbai- 400004, India.

+91-22-40560560
ombudsman@bdrpharma.com

Disclaimer: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and its liability is at the buyer's risk. Products currently covered by valid patents in India are offered for R&D purpose in accordance with Section 107(A) of the Patents Act, 1970.

© BDR Pharmaceuticals International Pvt. Ltd, All Rights Reserved. Designed By Ideamagix.

Terms & Conditions | Privacy Policy

  • Home
  • About Us
    • Overview
    • Our Strengths
    • Achievements
    • CSR Sustainability
    • Milestones
    • CMD Profile
    • Facilities
    • Mission & Vision
    • Global Presence
    • News
    • Press Release
    • Ethical Marketing Division
    • Board Of Directors
    • Blogs
    • Company Policies
  • Products
  • Expertise
    • Innovation & Technology
    • Regulatory
    • Research & Development
    • IPR
    • Quality Policy
    • Contract Manufacturing
  • Careers
    • Culture
    • Job Openings
  • Investors
  • Contact